Equities analysts expect Quintiles Transitional Holdings Inc. (NYSE:Q) to report earnings of $1.14 per share for the current fiscal quarter, according to Zacks Investment Research. Nine analysts have provided estimates for Quintiles Transitional Holdings’ earnings. The highest EPS estimate is $1.16 and the lowest is $1.13. Quintiles Transitional Holdings reported earnings of $1.00 per share during the same quarter last year, which indicates a positive year over year growth rate of 14%. The firm is scheduled to report its next quarterly earnings results on Wednesday, November 1st.
According to Zacks, analysts expect that Quintiles Transitional Holdings will report full-year earnings of $4.57 per share for the current fiscal year, with EPS estimates ranging from $4.53 to $4.62. For the next year, analysts expect that the firm will post earnings of $5.22 per share, with EPS estimates ranging from $4.85 to $5.50. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that that provide coverage for Quintiles Transitional Holdings.
Quintiles Transitional Holdings (NYSE:Q) last issued its earnings results on Thursday, August 3rd. The medical research company reported $1.09 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.05 by $0.04. Quintiles Transitional Holdings had a net margin of 0.82% and a return on equity of 15.68%. The firm had revenue of $1.97 billion for the quarter, compared to analysts’ expectations of $1.96 billion. During the same quarter last year, the company posted $0.93 earnings per share. Quintiles Transitional Holdings’s revenue was up 68.7% on a year-over-year basis.
A number of brokerages have recently issued reports on Q. Zacks Investment Research upgraded shares of Quintiles Transitional Holdings from a “hold” rating to a “buy” rating and set a $101.00 target price on the stock in a research report on Thursday, July 27th. Citigroup Inc. upped their target price on shares of Quintiles Transitional Holdings from $96.00 to $97.00 and gave the stock a “neutral” rating in a research report on Monday. William Blair upgraded shares of Quintiles Transitional Holdings from a “market perform” rating to an “outperform” rating and upped their target price for the stock from $70.10 to $93.42 in a research report on Friday. Barclays PLC set a $100.00 target price on shares of Quintiles Transitional Holdings and gave the stock a “buy” rating in a research report on Friday. Finally, Jefferies Group LLC reiterated a “hold” rating and set a $94.00 target price on shares of Quintiles Transitional Holdings in a research report on Friday. Eleven investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Quintiles Transitional Holdings has a consensus rating of “Hold” and an average target price of $89.94.
TRADEMARK VIOLATION NOTICE: “Brokerages Anticipate Quintiles Transitional Holdings Inc. (NYSE:Q) Will Post Earnings of $1.14 Per Share” was posted by BNB Daily and is the property of of BNB Daily. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at https://www.baseball-news-blog.com/2017/08/19/brokerages-anticipate-quintiles-transitional-holdings-inc-nyseq-will-post-earnings-of-1-14-per-share-updated.html.
In related news, Director Jack M. Greenberg sold 6,092 shares of the stock in a transaction on Wednesday, May 17th. The shares were sold at an average price of $82.50, for a total transaction of $502,590.00. Following the completion of the transaction, the director now owns 2,930 shares in the company, valued at $241,725. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Cpp Investment Board Private H sold 7,131,165 shares of the stock in a transaction on Wednesday, May 31st. The stock was sold at an average price of $84.01, for a total transaction of $599,089,171.65. The disclosure for this sale can be found here. Insiders have sold 8,850,560 shares of company stock valued at $744,110,641 in the last 90 days. 6.40% of the stock is currently owned by corporate insiders.
A number of hedge funds have recently made changes to their positions in the stock. John G Ullman & Associates Inc. purchased a new stake in shares of Quintiles Transitional Holdings during the first quarter worth approximately $290,000. ProShare Advisors LLC purchased a new stake in shares of Quintiles Transitional Holdings during the first quarter worth approximately $229,000. Candriam Luxembourg S.C.A. boosted its stake in shares of Quintiles Transitional Holdings by 31.5% in the first quarter. Candriam Luxembourg S.C.A. now owns 22,313 shares of the medical research company’s stock worth $1,797,000 after buying an additional 5,340 shares in the last quarter. State of Alaska Department of Revenue purchased a new stake in shares of Quintiles Transitional Holdings during the first quarter worth approximately $244,000. Finally, DnB Asset Management AS boosted its stake in shares of Quintiles Transitional Holdings by 3.3% in the first quarter. DnB Asset Management AS now owns 89,621 shares of the medical research company’s stock worth $7,217,000 after buying an additional 2,900 shares in the last quarter. Hedge funds and other institutional investors own 91.83% of the company’s stock.
Shares of Quintiles Transitional Holdings (NYSE Q) traded down 0.57% during midday trading on Tuesday, hitting $90.67. 973,175 shares of the company’s stock traded hands. The company has a 50 day moving average price of $89.50 and a 200 day moving average price of $82.85. The firm has a market capitalization of $19.95 billion, a price-to-earnings ratio of 200.60 and a beta of 0.64. Quintiles Transitional Holdings has a 1-year low of $70.10 and a 1-year high of $92.54.
Quintiles Transitional Holdings declared that its Board of Directors has approved a stock buyback program on Wednesday, May 24th that allows the company to buyback $1.00 billion in shares. This buyback authorization allows the medical research company to reacquire up to 5.4% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s management believes its stock is undervalued.
Quintiles Transitional Holdings Company Profile
Quintiles IMS Holdings, Inc, formerly Quintiles Transnational Holdings Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Quintiles Transitional Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quintiles Transitional Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.